10-QPeriod: Q1 FY2024

Edwards Lifesciences Corp Quarterly Report for Q1 Ended Mar 31, 2024

Filed April 29, 2024For Securities:EW

Summary

Edwards Lifesciences Corporation reported solid revenue growth in the first quarter of 2024, with net sales increasing by 9.5% to $1.6 billion compared to the prior year. This growth was primarily driven by strong performance in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines. The company also incurred significant separation costs related to the planned spin-off of its Critical Care product group, impacting net income. Operationally, the company continues to invest in research and development, essential for its long-term growth strategy in structural heart disease and related therapies. While the company generated positive operating income, the reported net cash used in operating activities was negative, largely due to a substantial tax deposit made related to a contested tax matter. Investors should monitor the progress of the Critical Care spin-off and the resolution of ongoing tax disputes, which could have future financial implications.

Financial Highlights

50 data points
Beta

Revenue

$1.33B

78.4% Gross Margin

Net Income

$351.00M

26.4% Net Margin

EPS (Diluted)

$0.58

Total Assets

$9.74B

Cash & Equivalents

$1.23B

Free Cash Flow

-$118.80M

Financial Statements
Beta
Revenue$1.33B
Cost of Revenue$286.90M
Gross Profit$1.04B
R&D Expenses$256.70M
SG&A Expenses$428.40M
Operating Income$349.00M
Net Income$351.00M
EPS (Basic)$0.58
EPS (Diluted)$0.58
Shares Outstanding (Basic)601.60M
Shares Outstanding (Diluted)604.10M

Key Highlights

  • 1Net sales increased by 9.5% to $1.6 billion in Q1 2024 compared to Q1 2023, primarily driven by TAVR and TMTT product sales.
  • 2Transcatheter Mitral and Tricuspid Therapies (TMTT) saw a significant 75.2% increase in net sales, highlighting growth in this emerging area.
  • 3The company incurred $41.3 million in separation costs related to the planned spin-off of its Critical Care product group.
  • 4Diluted Earnings Per Share (EPS) was $0.58, a slight increase from $0.56 in the prior year period.
  • 5Net cash used in operating activities was $(53.5) million, significantly impacted by a $305 million tax deposit for contested tax liabilities.
  • 6The company ended the quarter with $1.22 billion in cash and cash equivalents, indicating a healthy liquidity position.
  • 7The company announced the completion of patient treatment in its PROGRESS pivotal trial for moderate aortic stenosis and received CE Mark approval for its Edwards SAPIEN 3 Ultra RESILIA valve in Europe.

Frequently Asked Questions

The primary driver of revenue growth was the strong performance of its Transcatheter Aortic Valve Replacement (TAVR) products, particularly the Edwards SAPIEN platform, along with significant growth in Transcatheter Mitral and Tricuspid Therapies (TMTT) sales.

The company incurred $41.3 million in separation costs related to the planned spin-off of its Critical Care product group. Additionally, there are ongoing legal and tax-related expenses that require careful monitoring.

Edwards Lifesciences is actively contesting a notice of deficiency from the IRS for tax years 2015-2017, related to transfer pricing. The company made a significant deposit of $305 million in March 2024 to mitigate interest on potential liabilities while preparing for judicial proceedings. Similar disputes may arise for tax years 2018-2023. An assessment of approximately $110 million has also been claimed by the Israel Tax Authority.

The company announced its intention to spin off the Critical Care product group, expected to be completed near the end of 2024, subject to customary conditions. Significant separation costs of $41.3 million were incurred in Q1 2024 related to this process.